Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Fennec Pharmaceuticals Inc Market Cap
From what 1 stock analysts predict, the share price for Fennec Pharmaceuticals Inc (FENC) might increase by 195.24% in the next year. This is based on a 12-month average estimation for FENC. Price targets go from $13 to $22. The majority of stock analysts believe FENC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assignedFENC 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Fennec Pharmaceuticals Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on FENC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of FENC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $13 | Maintains | Aug 22, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $15 | Maintains | Aug 14, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $15 | Maintains | May 15, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $17 | Maintains | May 15, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $18 | Maintains | Apr 4, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $18 | Maintains | Mar 18, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $17 | Maintains | Aug 4, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $18 | Reiterates | Jun 21, 2023 |
| Charles Robertson II Cantor Fitzgerald | Overweight | $16 | Maintains | Apr 6, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $18 | Reiterates | Apr 4, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $18 | Reiterates | Mar 31, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $18 | Reiterates | Jan 26, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $12 | Upgrade | Nov 22, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $18 | Maintains | Oct 20, 2022 |
| David Nierengarten Wedbush | Outperform | $19 | Maintains | Sep 26, 2022 |
| Naureen Quibria Capital One | Overweight | $11 | Initiates | Sep 7, 2022 |
| Chase Knickerbocker Craig-Hallum | Buy | $14 | Assumes | Aug 8, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $14 | Maintains | Jun 3, 2021 |
Craig-Hallum | Buy | Initiates | Apr 21, 2021 | |
Maxim Group | Buy | Initiates | Apr 19, 2021 |
When did it IPO
N/A
Staff Count
29
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Rostislav Raykov
Market Cap
$155.7M
In 2023, FENC generated $21.3M in revenue, which was a increase of 1,284.50% from the previous year. This can be seen as a signal that FENC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
